China Fundamental Acquisition Corporation Announces Signing of Letter of Intent for Business Combination
|
| Posted
:
Mon, 09 Nov 2009 14:30:57 GMT |
| Author
:
China Fundamental Acquisition Corporation |
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
|
|
|
|
HONG KONG, Nov. 9 /PRNewswire-Asia/ -China Fundamental Acquisition
Corporation (OTC Bulletin Board: CFQUF; CFQCF; CFQWF; the "China Fundamental")
announced today that it has signed a letter of intent with a company with its
principal business operations in the People' Republic of China for a business
combination (the "Target"). China Fundamental will make an additional
announcement in the event it enters into a definitive agreement with the
Target. Pursuant to the China Fundamental's amended and restated Articles of
Association, it now has until May 20, 2010 to complete the business
combination. If China Fundamental is unable to complete the business
combination by May 20, 2010, it must then liquidate or seek shareholder
approval to extend the time period to complete a business combination to May
20, 2011.
Forward Looking Statements
Any statements contained in this press release that do not describe
historical facts constitute forward-looking statements as that term is defined
by the United States Private Securities Litigation Reform Act of 1995. Any
such forward-looking statement contained herein is based on current
expectations, but is subject to a number of risks and uncertainties that may
cause actual results to differ materially from expectations such as material
adverse events affecting China Fundamental or the ability to satisfy the
conditions to complete a business combination, and those other risks and
uncertainties detailed in its filings with the United States Securities and
Exchange Commission.
About China Fundamental Acquisition Corporation
China Fundamental Acquisition Corporation was organized under the laws of
Cayman Islands on December 12, 2007 as a blank check company to serve as a
vehicle to effect a merger, capital stock exchange, asset acquisition, stock
purchase or other similar business combination, or contractual arrangement
with an operating business having its primary operations in the People's
Republic of China.
SOURCE China Fundamental Acquisition Corporation
|
Copyright © 2008
PR Newswire. All rights reserved.
|
|
|
|
|
Related
News
Noah Education Files Form 20-F for Fiscal Year 2009
SHENZHEN, China, Nov. 23 /PRNewswire-Asia-FirstCall/ -- Noah Education
Holdings Ltd. (NYSE: NED) ("Noah" or "the Company"), a leading provider of
interactive educational content and education services in China, tod...
Controversial Award-Winning Film Obsession Available for Free Online Streaming
NEW YORK, Nov. 23 /PRNewswire/ -- The producers of Obsession Radical Islam's War Against the West are making the full-length feature documentary available for online viewing free of charge over Thanksgiving weekend.
The film, whose retail price is $19.95, ...
Victory Pharma, Inc. Announces Launch of NAPRELAN(R) Dose Card
SAN DIEGO, Nov. 23 /PRNewswire/ -- Victory Pharma, Inc. ("Victory") announced today the launch of NAPRELAN® Dose Card, a further extension of Victory's NAPRELAN franchise.
NAPRELAN Dose Card is designed for patients who require relief from mild to moderate pai...
Fragmentation Prevention and Energy Savings BURBANK, CA -- 11/23/09 --
For many years, conservation of energy has been
a serious issue. It traces back to our natural resources such as coal and
water and the amount of carbon being released in to the atmosphere, but it
also has a more practica..
Mediasite by Sonic Foundry Named Best Webcasting/Presentations Solution by Streaming Media Readers
MADISON, Wis., Nov. 23 /PRNewswire/ -- Mediasite by Sonic Foundry, Inc. (Nasdaq: SOFOD), the recognized market leader for rich media webcasting and knowledge management, has been voted Best Webcasting/Presentations Solution in the ...
RXi Pharmaceuticals Wins 2009 RNAi Technology Innovation of the Year Award from Frost & Sullivan WORCESTER, Mass. -
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical
company pursuing the development and commercialization of proprietary
therapeutics based on RNA interference (RNAi), today reported that the
Company has received Frost & Sullivan’s 2009 North Ame
SciClone Announces Enrollment Completion in Phase 2 Oral Mucositis Trial of SCV-07 FOSTER CITY, CA -- 11/23/09 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that patient enrollment is complete ahead of schedule
for its phase 2 trial of SCV-07 -- a small molecule synthetic peptide with
immunomodulating propertie..
|
|
|
|
|
|
|
|
|